TickerGuard
Buy Day today: Neutral (59) Mixed market breadth · major macro event coming up
ONC

BeiGene, Ltd.

Healthcare · Biotechnology

356.00$ -0.8% vs. previous close Closing price · As of: Aug 13, 2026

Statements

Segments

US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of BeiGene, Ltd. (ONC). It shows which part of the business is growing — and which one is holding it back.

Revenue by region

Revenue by region — ONC
Segment 2020 2021 2022 2023 2024 2025
U.S. $18.2M 5.9% $495.3M 42.1% · +2,617.1% $502.6M 35.5% · +1.5% $1.13B 45.9% · +124.5% $1.96B 51.4% · +73.5% $2.88B 53.9% · +47.1%
PRC $290.6M 94.1% $517.1M 44.0% · +77.9% $840.0M 59.3% · +62.4% $1.10B 44.8% · +31.2% $1.41B 37.0% · +28.1% $1.68B 31.4% · +19.0%
Europe- total revenue $163.1M 13.9% $63.3M 4.5% · -61.2% $202.0M 8.2% · +219.4% $362.6M 9.5% · +79.5% $611.4M 11.4% · +68.6%
Other $26.6M 1.1% $78.8M 2.1% · +196.3% $171.8M 3.2% · +118.0%
Other $0 0.0% $863.0K 0.1% $10.0M 0.7% · +1,059.4%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Revenue by product line

Revenue by product line — ONC
Segment 2019 2020 2021 2022 2023 2024 2025
Product revenue, net $308.9M 100.0% $634.0M 53.9% · +105.3% $1.25B 88.6% · +97.9% $2.19B 89.1% · +74.5% $3.78B 99.2% · +72.6% $5.28B 98.9% · +39.8%
Collaboration revenue $0 $0 0.0% $542.3M 46.1% $161.3M 11.4% · -70.3% $268.9M 10.9% · +66.7% $30.7M 0.8% · -88.6% $61.0M 1.1% · +98.6%
Research and development service revenue $0
Other $0
License revenue $0 0.0%
Right to access intellectual property revenue $0 0.0%

Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.

Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?